Gcanrx soon will open a Phase 2 clinical trial of a neuroprotective cannabinoid treatment that the company expects could benefit people with a range of neurological conditions, including Parkinson’s disease. The safety and efficacy trial, approved to take place in Israel, is expected to begin enrolling children with…
News
An approach for treating dysphagia — called effortful swallow maneuver — did not consistently ease signs of swallowing difficulties for Parkinson’s disease patients in a small pilot study. Effortful swallow, or ES, refers to a practice where patients are asked to consciously increase the force they use when swallowing…
People with Parkinson’s disease tend to have different coping strategies depending on factors such as age, gender, and education, a new study shows. Findings suggest that differences in demographic and clinical factors, but not differences in coping strategies, are the main factors that determine patients’ quality of life, according…
The Center for Movement Disorders and Neurorestoration at the University of California (UC) Davis Health Department of Neurology will serve as a Parkinson’s Foundation Center of Excellence starting this month and for at least the next five years. The center joins a Global Care Network that’s grown…
The U.S. Food and Drug Administration (FDA) is asking for more information concerning the safety of  IPX203, an extended-release oral formulation of carbidopa and levodopa, before a final approval decision in treating Parkinson’s disease symptoms can be made. In a complete response letter to Amneal Pharmaceuticals,…
Researchers have created a system that could be developed to allow at-home measuring of levodopa levels in people with Parkinson’s disease. The system was described in the study “Smartphone-based detection of levodopa in human sweat using 3D printed sensors,” published in Analytica Chimica Acta.
An algorithm can accurately identify people who are at increased risk of developing Parkinson’s-like motor problems in coming years, a new study shows. The study, “The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson’s Disease,” was published in Movement Disorders. The…
The early appearance of minor hallucinations in people with Parkinson’s disease might be a predictor of faster cognitive decline, a recent study suggests. Among those with hallucinations, cognitive decline was also associated with electrical activity in the frontal lobe, a part of the brain that controls cognition. The study,…
Changes in vision and eye health prior to deep brain stimulation (DBS) surgery can be a significant predictor of delirium in the hours after this Parkinson’s disease surgery, a study suggests. A post-operative risk of the psychiatric condition was found to be greater in older patients and those with…
Treatment with bemdaneprocel (BRT-DA01), BlueRock Therapeutics’s investigational cell-based therapy, was safe and well tolerated among patients with advanced-stage Parkinson’s disease, according to top-line results from a Phase 1 clinical trial. Furthermore, data also showed that transplantation was feasible, and there was evidence of cell survival and engraftment in…
Recent Posts
- Parkinson’s changed my uncle’s daily life, but his personality remained
- Developer targeting abnormal muscle tone in Parkinson’s with its VIM0423
- MJFF grants totaling $7.6M will help Casma develop Parkinson’s therapy
- Planning is key when traveling with Parkinson’s disease
- I’m an optimist, but sometimes Parkinson’s fatigue is too much